Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits

BackgroundPatients with locally advanced prostate cancer (LAPCa) received docetaxel-based neoadjuvant chemo-hormonal therapy (NCHT) had better clinical outcomes after surgery compared to neoadjuvant hormonal therapy (NHT) groups, but not all patients experienced favorable clinical outcomes with NCHT...

Full description

Bibliographic Details
Main Authors: Yinjie Zhu, Liancheng Fan, Hanjing Zhu, Yiming Gong, Chenfei Chi, Yanqing Wang, Jiahua Pan, Baijun Dong, Wei Xue
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
predictive signature
locally advanced prostate cancer
transcriptomic profiling
neoadjuvant chemo-hormonal therapy
neoadjuvant hormonal therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.963411/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.963411/full

Similar Items